NASH grows as indication for liver transplant

While hepatitis C (HCV) currently remains the leading indication for liver transplant in Australia and New Zealand, non-alcoholic steatohepatitis (NASH) is expected to eventually take over given the drivers of overweight, obesity and diabetes. NASH currently sits third behind both HCV and alcoholic liver disease. A review of more than 5,000 adults activated for liver ...

Already a member?

Login to keep reading.

© 2021 the limbic